ライフサイエンスコーパス: supraventricular

1 bundle branch (RB) for diagnoses of various supraventricular and fascicular tachycardias.

2 nitors showed a significant increase in both supraventricular and supraventricular plus ventricular b

3 or flutter (AF), myocardial infarction (MI), supraventricular and ventricular arrhythmias, venous thr

4 nderwent 744 catheter ablation procedures of supraventricular and ventricular arrhythmias.

5 ion rate cutoffs, and discriminating between supraventricular and ventricular arrhythmias.

6 hmic agent commonly used in the treatment of supraventricular and ventricular tachyarrhythmias.

7 shown the effectiveness of AZ for therapy of supraventricular and ventricular tachycardia (VT).

8 An additional arrhythmia, all supraventricular, appeared in 11 (22%) infants.

9 n our study, 14 (93%) manifested arrhythmia: supraventricular arrhythmia (13 of 15), including sick s

10 essor exposure may also decrease the risk of supraventricular arrhythmia (odds ratio, 0.55; 95% CI, 0

11 of skeletal muscle involvement (p < 0.001), supraventricular arrhythmia (p = 0.003), conduction defe

12 available on risk factors for perioperative supraventricular arrhythmia (SVA) after noncardiac surge

13 the right atrium caused repeated attacks of supraventricular arrhythmia and a strikingly reduced car

14 chycardia represents the most common regular supraventricular arrhythmia in humans, and catheter abla

15 use, and the first inappropriate shock for a supraventricular arrhythmia or death from any cause.

16 t tachycardia is an infrequently encountered supraventricular arrhythmia that continues to present di

17 Atrial fibrillation (AF) is the most common supraventricular arrhythmia that, for unknown reasons, i

18 Supraventricular arrhythmia was associated with a 33% in

19 Left ventricular dysfunction and supraventricular arrhythmia were the most commonly repor

20 ad a history of atrial fibrillation or other supraventricular arrhythmia, 510 had an implantable card

21 arrhythmia, 7.79% (95% CI, 4.87%-11.27%) for supraventricular arrhythmia, 8.68% (95% CI, 2.26%-17.97%

22 to that of the human, including induction of supraventricular arrhythmia.

23 months and before recurrence of symptomatic supraventricular arrhythmia.

24 t recurrence of a symptomatic ECG-documented supraventricular arrhythmia.

25 pleted follow-up or documented a symptomatic supraventricular arrhythmia.

26 ent of specific therapies for other forms of supraventricular arrhythmia.

27 were changes in medication/nonadherence and supraventricular arrhythmia.

28 Atrial fibrillation (AF) is a common supraventricular arrhythmia.

29 focus on decreases in ejection fraction and supraventricular arrhythmia.

30 phy that could explain an increased risk for supraventricular arrhythmia.

31 e salbutamol group had a higher incidence of supraventricular arrhythmias (26 vs. 10%; p = 0.2).

32 on disturbances (61% and 44%, respectively), supraventricular arrhythmias (69% and 52%, respectively)

33 Supraventricular arrhythmias (junctional ectopic tachyca

34 inib was associated with higher reporting of supraventricular arrhythmias (SVAs) (ROR: 23.1; 95% conf

35 Children with incessant tachyarrhythmias (supraventricular arrhythmias [n=26], junctional ectopic

36 ts had at least one catheter ablation; 5 for supraventricular arrhythmias and 2 for ventricular arrhy

37 otein levels and determine susceptibility to supraventricular arrhythmias and changes in cardiac stru

38 ycoprotein progranulin on the development of supraventricular arrhythmias and changes to cardiac func

39 y be valuable for the long-term treatment of supraventricular arrhythmias and control of ventricular

40 The supraventricular arrhythmias and their treatment are des

41 Supraventricular arrhythmias are frequently encountered

42 anding of how this molecular defect leads to supraventricular arrhythmias could influence the develop

43 Supraventricular arrhythmias developed over lifetime in

44 The supraventricular arrhythmias include a wide spectrum of

45 in the two groups, but neurologic events and supraventricular arrhythmias remained more frequent in t

46 The recurrence rate of total supraventricular arrhythmias was significantly lower in

47 trial dilatation up to giant size; (3) early supraventricular arrhythmias with progressive loss of at

48 1] and 1.13 (95% CI 1.05-1.22; P = .001) for supraventricular arrhythmias, 1.09 (95% CI 1.01-1.19; P

49 developed atrial fibrillation, 2 (5%) other supraventricular arrhythmias, and 10 (25%) were diagnose

50 ibrillation/flutter, bradyarrhythmias, other supraventricular arrhythmias, and ventricular arrhythmia

51 Co-primary study outcomes were supraventricular arrhythmias, bradyarrhythmias, and vent

52 Ventricular and supraventricular arrhythmias, heart failure events, redu

53 y has been implicated in the pathogenesis of supraventricular arrhythmias, including atrial fibrillat

54 nhibition shows promise for the treatment of supraventricular arrhythmias, the absence of subtype-sel

55 n the range previously reported for standard supraventricular arrhythmias.

56 edications and the recurrence of symptomatic supraventricular arrhythmias.

57 s a basis for localized AV nodal reentry and supraventricular arrhythmias.

58 n defects, left ventricular dysfunction, and supraventricular arrhythmias.

59 bnormalities suggestive of susceptibility to supraventricular arrhythmias.

60 ly hazard of increased neurologic events and supraventricular arrhythmias.

61 roved for the treatment of heart failure and supraventricular arrhythmias.

62 ed in 17 subjects because of hypertension or supraventricular arrhythmias.

63 rt surgery to control 2 common postoperative supraventricular arrhythmias.

64 used to control the ventricular response to supraventricular arrhythmias.

65 ion, including particulate matter, may cause supraventricular arrhythmias.

66 e that air pollution is also associated with supraventricular arrhythmias.

67 The CS has been implicated in a variety of supraventricular arrhythmias.

68 of adenosine administration as a test for a supraventricular as opposed to ventricular tachycardia w

69 e renal failure (41 [3.2%] vs 33 [2.5%]) and supraventricular cardiac arrhythmia (12 [0.9%] vs 13 [1.

70 Holter-detected PACs were defined as any supraventricular complexes occurring >30% earlier than e

71 rmally conducted QRS complexes (NQRS) and to supraventricular complexes with left or right bundle-bra

72 The length of the supraventricular crest is 29.1 +/- 6.9 mm, and it narrow

73 The vast majority do not have signs of supraventricular disease manifestations.

74 observed in 19% of relatives, whereas other supraventricular dysrhythmias were present in 16%.

75 Excessive supraventricular ectopic activity (ESVEA) was defined as

76 ne-associated arrhythmias were mainly single supraventricular ectopic beats.

77 We assessed the profile of ventricular and supraventricular ectopy and bradyarrhythmia on ambulator

78 ar ectopy, supraventricular tachycardia, and supraventricular ectopy.

79 d 3 degrees atrioventricular (A-V) block and supraventricular escape rhythm.

80 related serious adverse events (lethargy and supraventricular extrasystoles).

81 dered possibly related to treatment (grade 2 supraventricular extrasystoles).

82 The incidence of a composite of supraventricular (>30 seconds) and ventricular (>3 beats

83 hythmia (asystole, heart block, bradycardia, supraventricular or ventricular tachycardia) developed.

84 gnificantly associated with the frequency of supraventricular (P = 0.033) and ventricular (P = 0.026)

85 ficant increase in both supraventricular and supraventricular plus ventricular beats when the dietary

86 Accelerated supraventricular rates suppress VAs in 2 CPVT mouse mode

87 s, including ventricular (n = 27 [0.9%]) and supraventricular rhythm disorders (n = 22 [0.7%]), sever

88 AA assessed in gray and white matter (from a supraventricular slab) would relate to laboratory measur

89 evaluated a new algorithm for discriminating supraventricular (SVT) and ventricular (VT) tachycardias

90 gnosed with BPD, PSZ or GTSZ where free from supraventricular (SVT) or VT during the 6-month baseline

91 simendan group than in the placebo group had supraventricular tachyarrhythmia (3.1% vs. 0.4%; absolut

92 Dose-limiting toxicities were supraventricular tachyarrhythmia and myelosuppression.

93 The primary outcome was ventricular or supraventricular tachyarrhythmia in the 24 hours after m

94 e to begin an antiarrhythmic drug while in a supraventricular tachyarrhythmia in whom sinus rhythm ha

95 s (1 myocardial infarction and 1 hypotensive supraventricular tachyarrhythmia), neither of which were

96 troke, heart failure, myocardial infarction, supraventricular tachyarrhythmia, and ventricular tachyc

97 also had episodes of atrial tachycardia and supraventricular tachyarrhythmia.

98 mechanical ventilation and a higher risk of supraventricular tachyarrhythmia.

99 right-sided congestive heart failure (n=8), supraventricular tachyarrhythmias (n=5), ventricular tac

100 our study were to determine the frequency of supraventricular tachyarrhythmias (SVTAs) among modifica

101 important role for these agents in reducing supraventricular tachyarrhythmias after cardiac surgery.

102 l flutter (IDAF) in patients presenting with supraventricular tachyarrhythmias after surgical correct

103 te for initiating antiarrhythmic therapy for supraventricular tachyarrhythmias and other benign forms

104 hycardia, and inappropriate shocks caused by supraventricular tachyarrhythmias or oversensing of sign

105 ontertiary-based HCM cohort, ventricular and supraventricular tachyarrhythmias were particularly freq

106 ion, atrial flutter, atrial tachycardia, and supraventricular tachyarrhythmias) among patients enroll

107 DCM associated with sinus node dysfunction, supraventricular tachyarrhythmias, conduction delay, and

108 ugs for management of ventricular as well as supraventricular tachyarrhythmias.

109 etter discrimination between ventricular and supraventricular tachyarrhythmias.

110 y of antitachycardia pacing, and to suppress supraventricular tachyarrhythmias.

111 placebo, without increases in ventricular or supraventricular tachyarrhythmias.

112 Sustained supraventricular tachycardia (> 12 h) and lower gestatio

113 llation with rapid ventricular response; (6) supraventricular tachycardia (>15 beats).

114 ats (166 [5.3%] versus 265 [8.3%]; P<0.001), supraventricular tachycardia (1413 [44.7%] versus 1752 [

115 entricular fibrillation (62%), AF (23%), and supraventricular tachycardia (15%).

116 0 consecutive patients presenting with fetal supraventricular tachycardia (17 managed prenatally, 13

117 versus 0.86 [95% CI, 0.28-1.75]; P=0.07) and supraventricular tachycardia (20 [95% CI, 12-31] versus

118 r for inappropriate shock (44%), followed by supraventricular tachycardia (36%), and then abnormal se

119 469; p < .0001) among initial rhythms, i.e., supraventricular tachycardia (60.7%), ventricular tachyc

120 had higher F1 scores for all classes except supraventricular tachycardia (CNN F1 score, 0.696 vs MUS

121 We randomly allocated adults presenting with supraventricular tachycardia (excluding atrial fibrillat

122 (HR, 0.97; 95% CI, 0.96-0.98; P < .001) and supraventricular tachycardia (HR, 0.96; 95% CI, 0.94-0.9

123 er first shocks due to sinus tachycardia and supraventricular tachycardia (HR: 0.97, p = 0.86) and no

124 01) and increases in hospitalizations for AF/supraventricular tachycardia (HR: 1.38; 95% CI: 1.35 to

125 n (n = 4), ventricular fibrillation (n = 6), supraventricular tachycardia (n = 1), and polymorphic ve

126 rial flutter (8/102, 8%), atrial tachycardia/supraventricular tachycardia (n=9/102, 9%), premature ve

127 Clinical variables associated with SCD were supraventricular tachycardia (odds ratio [OR], 3.5; 95%

128 odds ratio, 4.9 [95% CI, 2.6-7.6]; P<0.001), supraventricular tachycardia (odds ratio, 3.2 [95% CI, 1

129 tients (25%): fatigue (two), flushing (one), supraventricular tachycardia (one), and two non-drug-rel

130 related to survival when initial rhythm was supraventricular tachycardia (p = .04), negatively relat

131 pacing maneuvers in patients with paroxysmal supraventricular tachycardia (PSVT) in the electrophysio

132 logy and clinical significance of paroxysmal supraventricular tachycardia (PSVT) in the general popul

133 Pharmacologic termination of paroxysmal supraventricular tachycardia (PSVT) often requires medic

134 and efficacy during conversion of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm.

135 with documented but noninducible paroxysmal supraventricular tachycardia (PSVT) who have evidence of

136 Tecadenoson terminates induced paroxysmal supraventricular tachycardia (PSVT) without the clinical

137 n with AP-affiliated arrhythmias: paroxysmal supraventricular tachycardia (PSVT), atrial fibrillation

138 Paroxysmal supraventricular tachycardia (PSVT), defined as tachyarr

139 We reviewed supraventricular tachycardia (SVT) ablation in adult pat

140 Accessory pathways are a common cause of supraventricular tachycardia (SVT) and can lead to sudde

141 regarding recurrence risk among infants with supraventricular tachycardia (SVT) are limited.

142 Supraventricular tachycardia (SVT) causing heart failure

143 management, including catheter ablation, of supraventricular tachycardia (SVT) in a large series of

144 and sotalol for the treatment of refractory supraventricular tachycardia (SVT) in children <1 year o

145 progression of CHF caused by pacing-induced supraventricular tachycardia (SVT) in pigs.

146 Supraventricular tachycardia (SVT) is one of the most co

147 leven additional patients were recruited for supraventricular tachycardia (SVT) mapping, and seven of

148 appropriate shocks caused by misdetection of supraventricular tachycardia (SVT) remains a substantial

149 patients (8 male; age, 30.5+/-8 years) with supraventricular tachycardia (SVT) underwent catheter ab

150 e syndrome, recurrent episodes of paroxysmal supraventricular tachycardia (SVT) were analyzed to dete

151 lar rhythms, and inappropriate therapies for supraventricular tachycardia (SVT) were compared among 5

152 AF), and 30 patients undergoing ablation for supraventricular tachycardia (SVT) were compared with a

153 and 25 with various arrhythmias: 9 reentrant supraventricular tachycardia (SVT), 2 ventricular tachyc

154 00 PVCs, 74 (42%) had couplets, 67 (37%) had supraventricular tachycardia (SVT), and 56 (31%) had non

155 atrial fibrillation, all classifications of supraventricular tachycardia (SVT), and stroke among old

156 ced atrial fibrillation (AF)/atrial flutter, supraventricular tachycardia (SVT), or AE.

157 nitiation and termination of reentrant fetal supraventricular tachycardia (SVT), the most common form

158 llation (VF), and 1368 episodes (n=149) were supraventricular tachycardia (SVT).

159 r systole on the hemodynamic response during supraventricular tachycardia (SVT).

160 in adults, it accounts for 13% of pediatric supraventricular tachycardia (SVT).

161 radiofrequency ablation of various forms of supraventricular tachycardia after Mustard and Senning o

162 of primary adverse events for patients with supraventricular tachycardia and ventricular tachycardia

163 2%) of 81 (95% confidence interval, 0.3%-9%) supraventricular tachycardia and ventricular tachycardia

164 Most cases of supraventricular tachycardia are not life-threatening; t

165 The low incidence of SCD and low risk of supraventricular tachycardia argue against routine invas

166 e the electrophysiologic mechanisms of fetal supraventricular tachycardia at presentation and postnat

167 Fetal supraventricular tachycardia causes significant fetal an

168 thms with rates of 182 to 250 beats/min, and supraventricular tachycardia discriminators were used fo

169 proved highly effective for the treatment of supraventricular tachycardia during childhood and adoles

170 ardia, sustained ventricular tachycardia, or supraventricular tachycardia during dobutamine infusion

171 One patient developed supraventricular tachycardia during pregnancy and had co

172 One patient developed supraventricular tachycardia during the additional 2 min

173 Adenosine, the standard therapy for treating supraventricular tachycardia in children and adults with

174 pic tachycardia is a common cause of chronic supraventricular tachycardia in children and can be resi

175 al tachycardia (FAT) is an uncommon cause of supraventricular tachycardia in children.

176 Supraventricular tachycardia in infants can be refractor

177 lysis was to define the incidence of SCD and supraventricular tachycardia in patients with asymptomat

178 tachycardia was the predominant mechanism of supraventricular tachycardia in the fetus.

179 patients developed 38 relapses of paroxysmal supraventricular tachycardia in the ICU after initial co

180 rdiovascular complications during pregnancy: supraventricular tachycardia in two, heart failure in tw

181 The odds of supraventricular tachycardia increased by a factor of 36

182 ory pathway effective refractory periods and supraventricular tachycardia inducibility in recent inva

183 entriculoatrial conduction during paroxysmal supraventricular tachycardia is a useful diagnostic mane

184 hat the mechanism responsible for paroxysmal supraventricular tachycardia is atrial reentry utilizing

185 Supraventricular tachycardia is common after heart trans

186 though long-term management of most forms of supraventricular tachycardia lies primarily in the realm

187 The fetal supraventricular tachycardia mechanism was 1:1 atriovent

188 The supraventricular tachycardia mechanism was typical slow/

189 analysis and postnatal confirmation of fetal supraventricular tachycardia mechanisms have been limite

190 Supraventricular tachycardia mechanisms were evaluated b

191 ia (VT); 3) pre-excitation; and 4) sustained supraventricular tachycardia of any mechanism.

192 low-up ranging from 8 to 96 months), regular supraventricular tachycardia or benign atrial fibrillati

193 centages of both VT/VF (22.3% vs. 28.7%) and supraventricular tachycardia or other non-VT/VF event ep

194 care physician must have a keen awareness of supraventricular tachycardia patterns, mechanisms, preci

195 erwent 13 studies to successfully ablate all supraventricular tachycardia substrates in eight (73%) p

196 d AVNRT) as important potential effectors of supraventricular tachycardia susceptibility.

197 ould be more pronounced during an episode of supraventricular tachycardia than during normal rhythm.

198 h could empower patients to treat paroxysmal supraventricular tachycardia themselves outside of a hea

199 endpoint of time to conversion of paroxysmal supraventricular tachycardia to sinus rhythm for at leas

200 atrioventricular-nodal-dependent paroxysmal supraventricular tachycardia to sinus rhythm within 30 m

201 atrioventricular-nodal-dependent paroxysmal supraventricular tachycardia to sinus rhythm.

202 From the fetus with supraventricular tachycardia to the adolescent with vaso

203 d diagnostic criteria were used to determine supraventricular tachycardia type.

204 effectively and safely performed for certain supraventricular tachycardia types in addition to intraa

205 The risk of supraventricular tachycardia was 16 (95% CI, 10-24) even

206 total of 69% of patients were cannulated for supraventricular tachycardia with a median rate of 230 b

207 re included in the differential diagnosis of supraventricular tachycardia with aberrancy, and the use

208 ardia (LPF-VT) is frequently misdiagnosed as supraventricular tachycardia with aberrant right bundle

209 rioventricular conduction in 22 patients and supraventricular tachycardia with atrioventricular block

210 There was a high association of supraventricular tachycardia with atrioventricular block

211 In 44 patients with supraventricular tachycardia with no history of AF or ri

212 ast 18 years and had a history of paroxysmal supraventricular tachycardia with sustained, symptomatic

213 more importantly, in the definitive cure of supraventricular tachycardia with the use of catheter ab

214 ions converted 14 of 15 (93%) with reentrant supraventricular tachycardia, 2 of 2 with ventricular or

215 In patients with supraventricular tachycardia, a modified Valsalva manoeu

216 tained monomorphic VT, 20 polymorphic VT, 10 supraventricular tachycardia, and 3 malsensing episodes.

217 requent arrhythmia experienced in childhood, supraventricular tachycardia, and its variants.

218 Most participants had ventricular ectopy, supraventricular tachycardia, and supraventricular ectop

219 an internationally recommended treatment for supraventricular tachycardia, but cardioversion is rare

220 y decreased the risk of atrial fibrillation, supraventricular tachycardia, deep vein thrombosis, resp

221 hree requiring hospital admission (sustained supraventricular tachycardia, hypotension, suspected myo

222 ry fetal tachycardia, specifically reentrant supraventricular tachycardia, junctional ectopic, or ven

223 vent free, except for an isolated episode of supraventricular tachycardia, over an average 6-year fol

224 Prompted by symptoms of paroxysmal supraventricular tachycardia, patients self-administered

225 Among patients who have monthly episodes of supraventricular tachycardia, radiofrequency ablation wa

226 ythmia classes: atrial fibrillation, general supraventricular tachycardia, sinus bradycardia and sinu

227 ting of DCM, cardiac conduction disease, and supraventricular tachycardia, together with increased au

228 ode examination that required application of supraventricular tachycardia, ventricular fibrillation,

229 a, including atrial fibrillation or flutter, supraventricular tachycardia, ventricular tachycardia, p

230 atrioventricular-nodal-dependent paroxysmal supraventricular tachycardia, with diagnosis and timing

231 ablation of atrioventricular nodal reentrant supraventricular tachycardia.

232 tions, and shocks for atrial fibrillation or supraventricular tachycardia.

233 expensive treatment option for many forms of supraventricular tachycardia.

234 iofrequency ablation to treat other types of supraventricular tachycardia.

235 e while receiving long-term drug therapy for supraventricular tachycardia.

236 l tachycardia from other forms of paroxysmal supraventricular tachycardia.

237 s uncommon, occurring in 1% of patients with supraventricular tachycardia.

238 ymptom (42.2%), followed by heart murmur and supraventricular tachycardia.

239 low-up (1 to 7 years) of patients with fetal supraventricular tachycardia.

240 outside a health-care setting for paroxysmal supraventricular tachycardia.

241 drug for an episode of perceived paroxysmal supraventricular tachycardia.

242 r ablation with 2 previously misdiagnosed as supraventricular tachycardia.

243 ew consistent associations were observed for supraventricular tachycardia.

244 lation, complete AV block, heart failure and supraventricular tachycardia.

245 ithm; ventricular tachycardia/diagnosis; and supraventricular tachycardia/diagnosis.

246 cases that involve (1) differentiation from supraventricular tachycardia; (2) assessment for atypica

247 with tachycardia mechanisms in patients with supraventricular tachycardias (SVT).

248 ers are associated with a lower incidence of supraventricular tachycardias (SVTs) and ventricular arr

249 ical atrioventricular node-dependent long RP supraventricular tachycardias (SVTs) can be challenging.

250 lp the operator make the distinction between supraventricular tachycardias and these other forms of v

251 Supraventricular tachycardias are less common and are us

252 No supraventricular tachycardias converted to VT or ventric

253 IAT episodes were most frequently caused by supraventricular tachycardias in the TV-ICD group (n=83/

254 A total of 156 supraventricular tachycardias were reported involving 98

255 noson appears to terminate AV node-dependent supraventricular tachycardias without hypotension and br

256 bstantial data support a heritable basis for supraventricular tachycardias, but the genetic determina

257 effective treatment strategy for symptomatic supraventricular tachycardias, including ablation of aty

258 ence can help differentiate various forms of supraventricular tachycardias, namely atrioventricular n

259 Among the 73 supraventricular tachycardias, the test accurately predi

260 Three other patients had supraventricular tachycardias, with success in two and n

261 pathy (DCM), cardiac conduction disease, and supraventricular tachycardias.

262 ha(1D) L-type Ca(2+) channel is expressed in supraventricular tissue and has been implicated in the p

263 (WCTs) into ventricular tachycardia (VT) and supraventricular wide tachycardia via 12-lead ECG interp

264 A total of 212 WCTs (111 VT and 101 supraventricular wide tachycardia) from 104 patients wer